These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9156656)

  • 1. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
    Warzocha K; Wotowiec D
    Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense of oligonucleotides and the inhibition of oncogene expression.
    Prins J; de Vries EG; Mulder NH
    Clin Oncol (R Coll Radiol); 1993; 5(4):245-52. PubMed ID: 8398922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Control of gene expression by antisense nucleic acids].
    Lebleu B; Clarenc JP; Degols G; Leonetti JP; Milhaud P
    C R Seances Soc Biol Fil; 1992; 186(5):560-6. PubMed ID: 1305901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene targets of antisense therapies in breast cancer.
    Yang DC; Elliott RL; Head JF
    Expert Opin Ther Targets; 2002 Jun; 6(3):375-85. PubMed ID: 12223074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T
    Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense strategies for the treatment of hematological malignancies and solid tumors.
    Kronenwett R; Haas R
    Ann Hematol; 1998; 77(1-2):1-12. PubMed ID: 9760146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides.
    Hélène C
    Eur J Cancer; 1991; 27(11):1466-71. PubMed ID: 1835863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides for haematological malignancies.
    Cotter FE
    Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
    [No Abstract]   [Full Text] [Related]  

  • 12. The potential application of ribozymes for the treatment of hematological disorders.
    James HA
    J Leukoc Biol; 1999 Sep; 66(3):361-8. PubMed ID: 10496304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense therapy.
    Narayanan R; Akhtar S
    Curr Opin Oncol; 1996 Nov; 8(6):509-15. PubMed ID: 8971471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of protein kinase C-alpha in hematologic malignancies.
    Lahn M; Sundell K; Köhler G
    Acta Haematol; 2006; 115(1-2):1-8. PubMed ID: 16424642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.
    Barton CM; Lemoine NR
    Br J Cancer; 1995 Mar; 71(3):429-37. PubMed ID: 7880719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense-protein kinase A: a single-gene-based therapeutic approach.
    Cho-Chung YS; Nesterova M; Kondrashin A; Noguchi K; Srivastava R; Pepe S
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):217-23. PubMed ID: 9212914
    [No Abstract]   [Full Text] [Related]  

  • 18. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor of apoptosis proteins in hematological malignancies.
    Fulda S
    Leukemia; 2009 Mar; 23(3):467-76. PubMed ID: 19039324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.